{"id":"W4405045156","doi":"10.1182/blood-2024-204962","title":"Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Institutes of Health; Bausch Health; Novo Nordisk; CSL Behring; Bristol-Myers Squibb; Agios Pharmaceuticals; State of Connecticut Department of Public Health; Health Resources and Services Administration; bluebird bio","keywords":"Medicine; Vaso-occlusive crisis; Incidence (geometry); Internal medicine; Disease; Sickle cell anemia; Surgery; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001346386,0.0002076954,0.0003679054,0.0001193618,0.00005046081,0.00002269686,0.0001133848,0.0001231082,0.00004679567],"category_scores_gemma":[0.0002175288,0.0001393313,0.0001075268,0.0004697405,0.0001392642,0.0001652305,0.00006113531,0.0003240664,0.00001885665],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003206191,"about_ca_system_score_gemma":0.000384163,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001310597,"about_ca_topic_score_gemma":0.000009828199,"domain_scores_codex":[0.9982886,0.00005864103,0.0004895136,0.0004236526,0.0004525598,0.0002869855],"domain_scores_gemma":[0.9992004,0.0001080319,0.0001151039,0.0003231451,0.0001074052,0.00014591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6527489,0.1206763,0.08308253,0.008729419,0.002662611,0.009098237,0.04811067,0.000551206,0.01553925,0.0009222051,0.0376661,0.02021261],"study_design_scores_gemma":[0.8631857,0.02040712,0.02197977,0.0069767,0.004209464,0.00002317253,0.003505601,0.0002149048,0.06797865,0.0007059415,0.009501893,0.001311084],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911435,0.003840404,0.00000670893,0.0006797372,0.0003018944,0.001019918,0.0001454236,0.0000684923,0.002793958],"genre_scores_gemma":[0.9986756,0.0003654762,0.0001546994,0.0000869932,0.0001154206,0.00002285693,0.0001188173,0.00003080989,0.0004292531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2104368,"threshold_uncertainty_score":0.5681765,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009739962490781705,"score_gpt":0.2706558433956806,"score_spread":0.2609158809048989,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}